Cita APA (7a ed.)
Kitajima, K., Okada, M., Kashiwagi, T., Yoshihara, K., Tokugawa, T., Sawada, A., . . . Yamakado, K. (2019). Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: What is the optimal timing for FDG-PET/CT? European Radiology, 29(7), 3935-3945.
Cita Chicago Style (17a ed.)
Kitajima, Kazuhiro, Masaya Okada, Toru Kashiwagi, Kyoko Yoshihara, Tazuko Tokugawa, Akihiro Sawada, Satoshi Yoshihara, Yoshihiro Fujimori, y Koichiro Yamakado. "Early Evaluation of Tumor Response to 90Y-ibritumomab Radioimmunotherapy in Relapsed/refractory B Cell Non-Hodgkin Lymphoma: What Is the Optimal Timing for FDG-PET/CT?" European Radiology 29, no. 7 (2019): 3935-3945.
Cita MLA (9a ed.)
Kitajima, Kazuhiro, et al. "Early Evaluation of Tumor Response to 90Y-ibritumomab Radioimmunotherapy in Relapsed/refractory B Cell Non-Hodgkin Lymphoma: What Is the Optimal Timing for FDG-PET/CT?" European Radiology, vol. 29, no. 7, 2019, pp. 3935-3945.
Precaución: Estas citas no son 100% exactas.